k¶¹Ç®°ü

English

Ó×¶øÃÜ´ó½ÒÃØ | sdLDL-CÊÇ2ÐÍÌÇÄò²¡¼°²¢·¢Ö¢µÄ·çÏÕÒò×Ó

°ä²¼ÓÚ£º2021-06-18

ÎÄÕÂÆðÔ´£º[ÖÐÎÄ]k¶¹Ç®°üÉúÎï



2ÐÍÌÇÄò²¡£¨T2DM£©»¼ÕßÓë΢Ѫ¹ÜºÍ´óѪ¹Ü²¢·¢Ö¢ÓйØ£¬ÕâЩ²¢·¢Ö¢»áµ¼ÖÂÐÄÄÔѪ¹ÜÎÊÌâ[1-3]¡£ÓÐ×êÑÐÅú×¢£¬ÌÇÄò²¡»¼Õß²úÉú¹Ú×´¶¯Âö¼²²¡£¨CAD£©ºÍÐ£ËÀ£¨MI£©µÄ·çÏÕÊǽ¡È«È˵Ä2~3±¶£¬84%µÄ¡Ý65ËêÌÇÄò²¡»¼ÕßËÀÓÚÐÄÔಡºÍ×äÖÐ[4]¡£´óÎÞÊý2ÐÍÌÇÄò²¡»¼ÕßѪ֬´úлÒì³££¬ÑªÖ¬Æ×ÌØµãΪ֬ÖÊÈýÁªÕ÷£¬¼´¸ÊÓÍÈýõ¥£¨TG£©Éý¸ß£¬¸ßÃܶÈÖ¬µ°°×µ¨¹Ì´¼£¨HDL-C£©½µÂä¡¢µÍÃܶÈÖ¬µ°°×µ¨¹Ì´¼£¨LDL-C£©Õý³£»òÇá¶ÈÉý¸ß£¬Ó×¶øÃܵÍÃܶÈÖ¬µ°°×£¨sdLDL£©¿ÅÁ£Ôö¶à¡£×êÑÐÏÔʾ£¬sdLDL-CµÄˮƽÊÇ2ÐÍÌÇÄò²¡¼°²¢·¢Ö¢µÄ·çÏÕÒò×Ó¡£


ƽ¶¥É½ÊÐÈËÃñÒ½ÔºÄÚÅÅйÓë´úл¿ÆµÄÌïÓµÈÈË[5]£¬ÕÐļÁËÔ̺¬352ÃûT2DM»¼Õߣ¨ÄÐ194Ãû£¬Å®158Ãû£¬¾ùÔÈ´ºÇï60.63Ë꣩ºÍ48Ãû½¡È«ÈË£¨ÄÐ34Ãû£¬Å®14Ãû£¬¾ùÔÈ´ºÇï45.38Ë꣩µÄÊÜÊÔÕß¡£Ì½Çó¶à»ùÒò¶à̬ÐÔ¡¢LDL-CºÍsdLDL-CÔÚT2DMÒ½ÖÎÖеÄÁÙ´²¼ÛÖµ¡£×êÑй¦·ò´Ó2018Äê5ÔÂÖÁ2020Äê1Ô¡£×êÑз¢ÏÖ£¬sdLDL-CÖØÒª´æÔÚÓÚT2DM»¼ÕßÌåÄÚ£¬ÇÒT2DM»¼ÕßsdLDL-CµÄ¾ùÔÈˮƽ¸ßÓÚ½¡È«ÈË¡£Ò½Öκó£¬LDL-CºÍsdLDL-CµÄ±í°×½ÏÒ½ÖÎǰ½µµÍÇÒ²î¾àÏÔÖø£¨p?


1

352ÀýÒ½ÖÎǰµÄT2DM»¼Õß¼°48Àý½¡È«ÈËLDL-CºÍsdLDL-CµÄ±í°×


3_bEeXPX

10ÀýT2DM»¼Õߣ¨ÄÐ6Àý£¬Å®4Àý£©Ò½ÖÎǰºó¼ì²âLDL-C£¬sdLDL-CµÄˮƽ¡£Êý×Ö1µ½10´ú±í²¡ÈË1µ½10


ÆëÆë¹þ¶ûҽѧԺ´ÓÊôµÚÈýÒ½ÔºµÄÑîÐã¾²µÈ[6]£¬½«146ÀýT2DM»¼£¨ÆäÖÐÄÐ85Àý£¬Å®61Àý£»´ºÇï30¡«70Ë꣩Öе¥´¿T2DM»¼Õß67ÀýΪ²¡Àý×é¢ñ£¬T2DM¼°²¢·¢Ö¢»¼Õß79ÀýΪ²¡Àý×é¢ò£»ÁíÑ¡ÔñͬÆÚ½¡È«Ìå¼ìÕß107Ãû×÷Ϊ¶ÔÕÕ×é¡£Á½×é¾ù½øÐÐsd LDL-C¡¢GLU¡¢TC¡¢TG¡¢LDL-C¡¢HDL-C¼ì²â¡£¹Û²ìT2DM¼°Æä²¢·¢Ö¢»¼ÕßѪÇåÖÐsdLDL-Cˮƽ±ä¶¯Çé¿ö²¢·ÖÎöÆäÁÙ´²ÀûÓüÛÖµ¡£×êÑÐÁ˾ÖÅú×¢£¬sd LDL-CÔÚT2DM»¼ÕßÖÐÉý¸ßÏÔÖø£¬sd LDL-CÓëTG¡¢TC¡¢LDL-C³ÊÕýÓйØÓëHDL-C³Ê¸ºÓйØ¡£¹Û²ìsd LDL-CµÄ±ä¶¯Çé¿ö¿ÉÓÃÓÚÔ¤²âT2DM²¢·¢Ö¢²¡±ä²úÉú·çÏÕ¡£


4_xwuNdi


¶«¾©´óѧ´óѧԺҽѧ×êÑÐÔºÐÄѪ¹ÜÄÚ¿ÆAtsuko NakayamaµÈÈË[7]£¬¶Ô¸ßµ¨¹Ì´¼ÑªÖ¢¹é²¢ÌÇÄò²¡ÊÓÍøÄ¤²¡±ä»¼ÕßµÄËûÍ¡ÀàÒ©ÎïÇ¿»¯Ò½ÖÎ×êÑУ¨n=5042£©½øÐÐÁË·ÖÎö£¬¸ú×Ù¹Û²ìÁË3.2¡À0.9Ä꣬ÆÀ¹ÀÁËÖ¬ÖÊÉ¢²¼ÓëÌÇÄò²¡ÊÓÍøÄ¤²¡±ä¼¤¹âÒ½ÖÎÐèÒªÖ®¼äµÄÓйØÐÔ¡£×êÑз¢ÏÖ£¬sdLDL-CµÄˮƽÓëÔØÖ¬µ°°×BµÄˮƽ³ÊÏÔÖøÕýÓйأ¨r=0.83£©£»sdLDL-CÊÇÔ¤²âCVÊÂÎñµÄÃô¸Ð±êÖ¾Îp£¼0.01£©£»sdLDL-CÊÇÔ¤²âѪ֬»¼ÕßÊÇ·ñ±ØÒª¼¤¹âÒ½ÖεÄÃô¸ÐÖ¸±ê£¨p=0.009£©¡£Á˾ÖÅú×¢£¬sdLDL-CÊÇÔ¤²â¸ßµ¨¹Ì´¼ÑªÖ¢ºÍÌÇÄò²¡ÊÓÍøÄ¤²¡±ä»¼ÕßÐÄѪ¹ÜÊÂÎñÒÔ¼°¼¤¹âÒ½ÖÎÐèÒªµÄÃô¸Ð°Ðµã±êÖ¾Îï¡£


5_qwpMBa

sdLDL-Cˮƽ¶ÔÐÄѪ¹ÜÊÂÎñµÄÀÛ»ýΣÏձȺÍÌÇÄò²¡ÊÓÍøÄ¤²¡±ä¼¤¹âÒ½ÖεıØÒªÐÔ


6_X9tIGy


k¶¹Ç®°üÉúÎïsd LDL-CÊÔ¼ÁºÐ

¹ýÑõ»¯Îïø·¨

7.webp_Rsmxeq


1. Ê×¼Ò×¢²á¼°¹úÄÚÍÆ¹ã£¬¿Í»§ÈϿɶȸߣ»

2. ¹ýÑõ»¯Îïø·¨£¬Ó볬¿ìÀëÐÄ·¨ÓÐÓÅÁ¼µÄÓйØÐÔ£¬¼ì²âÁ˾ÖÕýÈ·¡¢¼±¾ç£»

3. II bÐ͸ß֬Ѫ֢¡¢MetSµÈÌØÊâÑù±¾µÄ²âÖµ¸üÕýÈ·£»

4. ¿¹×ÌÈÅ»úÄÜÓÅ£¬¼ì²â»ÆðãÑù±¾²»ÊÜÓ°Ï죻

5. »ñµÃ2016ÄêÖйúÌå±íÕï¶ÏÊÔ¼Á´´Ð²úÆ·½±¡£


12.webp_qpMPgX


¡¾²Î¿¼Îļþ¡¿

[1] Seshasai SRK, Kaptoge S, Thompson A, et al. Diabetes mellitus, fasting glucose, and

risk of cause-specific death. N Engl J Med. 2011, 364(9), 829-41.

[2] American DA. Standards of medical care in diabetes-2015 abridged for primary care providers. Clin Diabetes. 2015, 33(2), 97-111.

[73] Turner RC, Millns H, Neil HA, et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ. 1998;316(7134):823¨C8.

[4] Îâ¼Î,Íô¿¡¾ü.Ó×¶øÃܵÍÃܶÈÖ¬µ°°×¼ì²â²½Öè¼°ÀûÓýøÕ¹[J].Öлª¼ìÑéҽѧÔÓÖ¾, 2017, 40(6), 417-419.

[5] Tian, Y., Wang, J., Liu, Y. et al. MassARRAY multigene screening combined with LDL-C and sdLDL-C detection for more favorable outcomes in type 2 diabetes mellitus therapy. BMC Med Genomics 14, 83 (2021). https://doi.org/10.1186/s12920-021-00937-8.

[6] º«Ë¬, ÑîÐã¾², ÖìÔÂÆ½, µÈ. sdLDL-CÔÚT2DM¼°Æä²¢·¢Ö¢»¼ÕßÖÐѪÇåˮƽ±ä¶¯¼°ÁÙ´²ÀûÓ÷ÖÎö[J]. ÆëÆë¹þ¶ûҽѧԺѧ±¨, 2019, 40(9), 1080-1081.

[7] Atsuko N, Hiroyuki M, Tatsuyuki S, et al. Small Dense Low-Density Lipoprotein Cholesterol is a Potential Marker for Predicting Laser Treatment for Retinopathy in Diabetic Patients. J Atheroscler Thromb. https://doi.org/10.5551/jat.62889



END

ÎÄÕÂÆðÔ´£ºk¶¹Ç®°üÉúÎï? |? Ôð±à£ºEcho ?|? У¶Ô£ºMiss Bio¡¢Dora



 
¡¾ÍøÕ¾µØÍ¼¡¿